GlassScriptPhysician profile
Robert A Latkany
NPI 1487681482
$12,995.99
in general payments reported to CMS, 2019-2025
18 companies · $4,166 in 2025
The $4,166 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $47.27 · 2021: $252 · 2022: $147 · 2023: $317 · 2024: $7,905 · 2025: $4,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $11K · Food and Beverage: $1,751 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $10,618.59 |
| Food and Beverage | $1,751.11 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oasis Medical, INC. | $10,618.59 | 2024-2025 | Oasis Tears |
| Bausch & Lomb Americas INC. | $520.24 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $393.53 | 2023-2025 | Tyrvaya |
| Abbvie INC. | $235.93 | 2022-2025 | |
| Alcon Vision LLC | $221.13 | 2024-2025 | Tryptyr, Eysuvis, Rocklatan |
| Sun Pharmaceutical Industries INC. | $172.88 | 2019-2025 | Cequa |
| Dompe US, INC. | $132.94 | 2023-2025 | Oxervate |
| Amgen INC. | $130.68 | 2024-2025 | Tepezza |
| Glaukos Corporation | $104.05 | 2021 | |
| Biotissue Holdings INC. | $98.85 | 2021-2025 | |
| Allergan, INC. | $84.73 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $80.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $52.76 | 2022-2023 | |
| Shire North American Group INC | $47.44 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $39.84 | 2025 | Xdemvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.26 | 2019 | |
| Harrow Eye, LLC | $21.35 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $17.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Latkany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.